GLP-1s' Effects on Cancer Risk May Be Influenced by Diabetes Severity
(MedPage Today) -- Diabetic patients treated with GLP-1 receptor agonists had a lower cancer risk versus insulin and sulfonylureas but not other diabetes medications, although the benefits varied by diabetes severity, a large cohort analysis with...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.